This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Use of a Lifeline Graft in the A-V Shunt Model

This study has been completed.
Information provided by (Responsible Party):
Cytograft Tissue Engineering Identifier:
First received: February 20, 2009
Last updated: July 15, 2013
Last verified: July 2013
This study will assess the safety and efficacy of a completely autologous and completely biological tissue engineered blood vessel (TEBV) called Lifeline™ used as an arteriovenous fistula for dialysis access.

Condition Intervention Phase
ESRD Hemodialysis Device: Lifeline Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of a Completely Autologous and Completely Biological Tissue Engineered Blood Vessel Lifeline as an Arteriovenous Fistula in Hemodialysis Patients - Safety and Efficacy Study.

Resource links provided by NLM:

Further study details as provided by Cytograft Tissue Engineering:

Primary Outcome Measures:
  • The primary purpose of this study will be to gain preliminary safety experience with Lifeline blood vessel as an arteriovenous fistula [ Time Frame: minimum 3 months ]

Secondary Outcome Measures:
  • The secondary purpose of the study is to assess the efficacy of the Lifeline blood vessel used as hemodialysis access in ESRD patients [ Time Frame: 36 months ]

Study Start Date: September 2004
Study Completion Date: December 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lifeline blood vessel Device: Lifeline
Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
Other Name: Tissue engineered blood vessel


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have signed an informed consent
  • Patients ≥ 21 years old
  • Patients not candidates for a Brescia-Cimino A-V fistula (own vessels)
  • Have an AV shunt or fistula that will likely fail within 12 months because of:

    • Signs of clinical dysfunction: increment of venous pressure, limited site of puncture, stenosis, aneurysm dilatations that cannot be surgically repaired or by other media, or
    • Previous angioplasty, or
    • Previous thrombolysis
  • Fall into category of ASA grade 2 or below (or UK equivalent)
  • Are willing and able to comply with 2, 4, 6, 8, 10, 12, 16, 20, 24, 36 and 52 week follow up and able to comply with biannual follow up thereafter.

Exclusion Criteria:

  • A need for urgent surgery
  • Penicillin allergy
  • Patients with uncontrolled hypertension
  • Morbid obesity (> 300 lbs)
  • Active systemic infection
  • Contraindication for anticoagulation
  • Coagulopathy
  • Acute renal failure
  • Connective tissue diseases (i.e. Marfan's syndrome)
  • Pregnant or nursing
  • Life expectancy < 1 year
  • Participation in another study involving an investigational device or new drug
  • Other medical, social or psychological issues that, in the opinion of the principal investigator, preclude them from receiving the treatment and the procedures/evaluations of the post-operative follow up
  • Inability or unwillingness to comply with the scheduled follow-up visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00850252

Instituto Argentino de Diagnostico y Tratamiento
Buenos Aires, Argentina
Department of General, Vascular and Transplant Surgery
Katowice, Poland
Sponsors and Collaborators
Cytograft Tissue Engineering
Principal Investigator: Luis M de la Fuente, MD IADT, Buenos Aires, Argentina
Principal Investigator: Lech Cierpka, MD PhD Department of General, Vascular and Transplant Surgery, Katowice, Poland
  More Information

Responsible Party: Cytograft Tissue Engineering Identifier: NCT00850252     History of Changes
Other Study ID Numbers: Cytograft A-V
R44HL064462-06 ( U.S. NIH Grant/Contract )
Study First Received: February 20, 2009
Last Updated: July 15, 2013

Keywords provided by Cytograft Tissue Engineering:
Tissue engineered blood vessel
A-V shunt

Additional relevant MeSH terms:
Glucuronyl glucosamine glycan sulfate
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 18, 2017